Kineta, Inc. (KA)
Company Description
Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives.
It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy.
The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug.
KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, head and neck, renal cell, and colorectal cancers.
It is also developing anti-CD27 agonist mAb immunotherapy, which is in preclinical development for advanced solid tumors, such as renal cell carcinoma, ovarian, and colorectal cancers.
The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. was founded in 2007 and is headquartered in Seattle, Washington.
Country | United States |
Founded | 2007 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 11 |
CEO | Craig W. Philips |
Contact Details
Address: 7683 Se 27th Street, Suite 481 Mercer Island, Washington 98040 United States | |
Phone | (206) 378-0400 |
Website | kinetabio.com |
Stock Details
Ticker Symbol | KA |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001445283 |
ISIN Number | US49461C1027 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Craig W. Philips | President |
Pauline Kenny Esq., J.D. | Advisor |
Keith A. Baker | Chief Financial Officer |
Dr. Thierry Guillaudeux Ph.D. | Chief Scientific Officer |
Gary Gentges | Executive Vice President of Corporate Development |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 21, 2024 | 10-K | Annual Report |
Mar 21, 2024 | 8-K | Current Report |
Mar 12, 2024 | 8-K | Current Report |
Feb 29, 2024 | 8-K | Current Report |
Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Feb 12, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jan 17, 2024 | 8-K | Current Report |
Jan 5, 2024 | 8-K | Current Report |
Dec 15, 2023 | 8-K | Current Report |